Curative Effect Analysis Of Recurrent Epithelial Ovarian Cancer

Object : 70% epithelial ovarian cancer are found in advanced stage,and 60-80% patients can acquire clinical complete remission through the normalized treatment.But for the most part of them will be relapse,and proportion of 25% of initial relapse are platinum-resistant recurrent ovarian cancer.Late found time.primary and secondary platinum-resistance led to the high mortality rate of ovarian cancer.Reccording to the time from the end of the last chemotherapy to ruccurrence,it is divided into platinum-sensitive recurrent ovarian cance and platinum-resistant recurrent ovarian cancer.NCCN clinical guideline still recommend platinum-based doublet but there is no standard chemotherapy regimen for platinum-resistant recurrent ovarian cancer.To explore effective chemotherapy scheme,this research summary and analyze platinum-resistant recurrent ovarian cancer treatment options of the tianjin medical university general hospital for recent 12 years.Comparative observate oxaliplatin in combination with ifosfamide regimen and gemcitabine monotherapy regimen in treatment of platinum-resistant recurrent epithelial ovarian cancer efficacy and safety.Methods: 1.Collect the recurrent ovarian cancer patients from Januraryof 2004 to june of2016,and analyze all the recurrent ovarian cancer.Divide platinum-sensitive recurrent ovarian cancer into three groups Group A:18patients secondary cytoreductive surgery andchemotherapy.Group B:39patientscarboplatin/cis-platinumandpaclitaxel/docetaxel/paclitaxelliposome.Group C:13patientsoxaliplatin+paclitaxel/docetaxel/paclitaxel liposome.Then divide platinum-resistant recurrent ovarian cancer into two groups.Group D: 16 patients,chemotherapy regimens were ifosfamide 0.5g/m2,2 d,oxaliplatin150 mg/m2,21 days for a course of treatment.Group E: 15 patients,chemotherapy regimens were gemcitabine 1.0 g/m2,weekly.2.Take the response evaluation criteria in solid tumors(RECIST)and serum CA125 level analyze the curative effect of two kinds of second-line chemotherapy regimens.Results divided into four categories: complete remission(CR),partial response(PR),stable disease(SD)and progressive disease(PD).Complete remission(CR)+ partial response(PR)were the total effective rate.3.Evaluate drugs safety with reference to the WHO standard for toxicity of anticancer.It divided into 0-IV.4.Statistical analysis was performed using SPSS24.0.Count data using percentage,compared by chi-square test,count measurement data using (?)±S,compared by analysis of variance,P < 0.05 was statistically significant.Survival analysis was performed by Kaplen Meier survival curve analysis.Results: 1.During the year 2004 to june of 2016,there are 119 patients with recurrent ovarian cancer.Total effective rate of A ?B?C groups were 83.3%?67.% ?61.7%,respectly p>0.05,without statistically significant.the result of adverse effct in three regimens is no obviously difference between the of nausea and vomiting or hematologic or peripheral nervous adverse reactions.The PFS were 13.1?9.3 and 10.0 months,Group A have difference between Group B and C,with statistically significant.2.Total effective rate of D?E group were43.75%?20% respectly.P >0.05,without statistically significant.The result of adverse effct in two second-line chemotherapy regimens:There is no obviously difference between the two second-line chemotherapy regimen of nausea and vomiting or hematologic adverse reactions.The PFS were 6.0and 5.0 months in oxaliplatin in combination with ifosfamide regimen and gemcitabine monotherapy respectly,without statistically significantConclusions: 1.Total effective rate of A ?B?C groups were 83.3%?66.7% ?61.5%,respectly p>0.05,without statistically significant.the result of adverse effct in three regimens is no obviously difference between the of nausea and vomiting or hematologic or peripheral nervous adverse reactions.The PFS were 13.1?9.3 and 10.0 months,Group A have difference between Group B and C,with statistically significant.2.Curative effect in oxaliplatin in combination with ifosfamide regimen and gemcitabine monotherapy were 43.75% and 20%,without statistically significant.The adverse effce of peripheral nerve injury were more common in oxaliplatin in combination with ifosfamide regimen.But all these sdverse effct can be tolerated.PFS were 6.0 and 5.0 months,all without statistically significant.